Shopping Cart
Remove All
Your shopping cart is currently empty
Garadacimab
(Synonyms: CSL312) Copy Product Info
🥰Excellent
Synonyms: CSL312
Catalog No. T77018 Copy Product Info
🥰Excellent
Garadacimab (CSL312) is a potent whole-human IgG4 monoclonal antibody targeting activation factor XII (FXIIa). Garadacimab can be used to study hereditary angioedema.
Garadacimab
Cas No. 2162134-62-3
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $313 | In Stock | In Stock | |
| 5 mg | $647 | In Stock | In Stock | |
| 10 mg | $987 | - | In Stock | |
| 25 mg | $1,460 | - | In Stock | |
| 50 mg | $1,970 | - | In Stock | |
| 100 mg | $2,660 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:100% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Garadacimab (CSL312) is a potent whole-human IgG4 monoclonal antibody targeting activation factor XII (FXIIa). Garadacimab can be used to study hereditary angioedema. |
| Targets & IC50 | β-FXIIa:140 pM(Kd) |
| In vitro | Garadacimab (CSL312) demonstrates high affinity to activated βFXIIa with a KD of 140 pM. In an activated partial thromboplastin time (aPTT) assay with human plasma, Garadacimab exhibits potency. Notably, it displays high selectivity over a panel of relevant human serine proteases, including FVIIa, FIXa, FXa, FXIa, kallikrein, tissue plasminogen activator, activated protein C, and urokinase plasminogen activator[2]. |
| In vivo | In male and female cynomolgus monkeys, Garadacimab (0.5, 1, and 3 mg/kg i.v. and 6 and 20 mg/kg s.c. over 8 weeks) shows a dose-dependent increase in plasma concentrations[1]. Garadacimab exhibits an inhibitory effect on FXII-mediated kallikrein activity. Moreover, it induces a clear dose-dependent prolongation of activated partial thromboplastin time (aPTT) with no associated effect on the prothrombin time[1]. |
| Endotoxin | <1.0 EU/mg |
| Synonyms | CSL312 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | F12/Factor XII |
| Molecular Weight | 146.5 kDa |
| Cas No. | 2162134-62-3 |
| Isotype | Human IgG1 lambda2 |
| Recommended Isotype Control |
| Storage | Store at low temperature -20°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Preview
Related Tags: Garadacimab in vivo | Garadacimab in vitro | Garadacimab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.